A small-scale human trial by Mayo Clinic researchers has shown for the first time that harmful senescent cells that accumulate with age can be removed from the body by senolytic drugs. This has been demonstrated many times already in mice, but this is the first confirmation that these drugs remove senescent cells in the same…

The topic for the September Edition of the Journal Club was the recent human trial of senolytic agents Dastatinib and Quercetin. For the researchers at the Mayo Clinic this was a follow on study from their previous human trial targeting IPF. This time the researchers ran a study to see how senolytics influenced diabetic kidney…

For the September Journal Club, we are taking a look at the new human trial data from the recent senolytics trial at Mayo Clinic, a follow-on study from its previous human trial targeting IPF. This time, the researchers ran a study to see how senolytics influenced diabetic kidney disease and if it actually removes senescent…

The results from a human pilot study that focused on treating idiopathic pulmonary fibrosis with senescent cell-clearing drugs has been published. The drugs target aged and damaged cells, which are thought to be a reason we age and get sick, and remove them from the body. Senescent cells and aging As we age, increasing numbers…

Today, we wanted to draw your attention to a recent study showing an association between the accumulation of Tau proteins, which are misfolded proteins that typically indicate Alzheimer’s disease and senescent cells. The researchers also showed that Tau pathology was improved by the use of drugs that remove non-dividing senescent cells. Unfortunately, this journal paper…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD